

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Joel R. Studin

Serial No.

10/829,315

Filed

April 21, 2004

Examiner

Sheikh, Humera N.

Art Unit

1615

Title

Method and Composition for the Treatment of Scars

Commissioner of Patents and Trademarks P.O. Box 1450

Alexandria, VA 22313-1450

DECLARATION OF JOEL R. STUDIN UNDER 37 C.F.R. §1.131

I do hereby declare as follows:

- 1. THAT I received a Bachelor of Science in General Science and Psychology from the University of Rochester, Rochester, NY, in 1975.
- 2. THAT I received a Doctor of Medicine from Mount Sinai Hospital, New York, NY, in 1982.
- 3. THAT I have practiced as a Plastic and Reconstructive Surgeon since 1987.
- 4. THAT I am the inventor of the above-identified application, that I am familiar with the above-identified application, the Office Actions and applied references rendered to date.
- 5. THAT Exhibit A is a Formula Worksheet from an independent laboratory I directed to prepare a formulation called Scar Guard, containing a corticosteroid in a film-forming carrier, prior to September 28, 1999. See Exhibit A, from which all dates and extraneous information have been redacted.
- 6. THAT Exhibit B is a Stability Report Sheet which shows stability testing results of Scar Guard formulation prior to September 28, 1999. See Exhibit B, from which all dates and extraneous information have been redacted.
- 7. THAT Exhibit C is a Facsimile Cover Page from a independent testing facility I directed to test Scar Guard, stating that "clinical testing on

psoriasis indicated that there was a transfer of the corticosteriod into the skin," prior to September 28, 1999. See Exhibit C, from which all dates and extraneous information have been redacted.

8. I further declare that all statements made herein to my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements so made may jeopardize the validity of the document, or application, or any patent issuing therefrom.

4.10.07

Respectifully submitted,

Joel R. Studin

	EXHIBIT
	a A
===:	Care Character of the

FORMULA WORKSHEET

	la : SCAR GUARD LIQ	Code:			
	Description : Schedule : - Days to exp. : 360	AWP per MLS: \$. Estimated time	to make:		COUNSELED:
	Where obtained: DFG	Date:	NDC:		
	Misc.: Therapy: Date made : / /	Made by:	1		by:
	Exp. date ://	Lot number:		Qty ma	ade: 100 MLS
	•	CHEMIC	בבב פ'דמי		
	Name	Form Quantity used un		Exp. Date	Mfg Ing.Cost
	XANTHAN GUM	PWDR .200 (ims		\$.0104
	1 GMS / #500 (formula qty) x #1	00 (qty made) = .2 GMS			
	HYDROCORTISONE MICONIZED (Sangaria)	PWDR . 1.000 (MS		\$1.0700
	5 GMS / #500 (formula qty) x #1				
		LIQ 10.000 A	4LS	/	\$1.7000
	50 MLS / #500 (formula qty) x #				•
a 50	COLLODION FLEXIBLE, USP/NF 15,500		1LS		\$2.1600
7 44 12	450 MLS / #500 (formula qty) x				
	# BRUSH APPLICATOR 15 ML			/	\$3.6040
	34 UNIT / #500 (formula qty) x			67 D/ +	60 51
		Estimated profit	t per batch \$	57.26 To	otal ing. cost \$8.54
	·				•
	•	,			

-----INSTRUCTIONS/NOTES--

- 1. PUT XANTHAN GUM & HC POWDER IN MORTAR & MIX WELL.
- 2. SLOWLY ADD SILICONE, MIXING WELL
- 3. SLOWLY ADD ABOUT 100ML OF FLEX COLLODION, MIXING WELL.
- 4. POUR RESULTANT MIXTURE IN A JAR & ADD REMAINING FLEX COLLODION AND SHAKE VIGOROUSLY UNTIL RESULTANT LIQUID IS HOMOGENIOUS.
- 5. SHAKE WELL & POUR SMALL AMOUNT INTO A BEAKER AND FILL 15ML BRUSH BOTTLES KEEP SHAKING & FILLING UNTIL ALL BOTTLES ARE FULL.



Stability Report Sheet

Produ	ct Description	Scar Gu	ard		·	•
Produc	t Lab Numbe	G229				
Odte	Manufactured Date Bottled	Unknow	1			
	Duta Bottlet	· · · · ·				
•			•	Date		
	Date started	Time in	Time out	Completed	Comments	
Ref Standard			1	Sempletes	Comments	Pass/Fail
Dark Stability				 		
Light Stability		.1	1.	<u> </u>		YN
Oven Stability	7					YN
स्राटमके प	.:	4:00pm	1:30Pm	Γ	Yellow, sectionent, off-color cap	TY (D)
month 2		T			Tellow, securioric, an color cap	
manth a	······································		1			YN
month 4						YN
Freeze/Thaw			,			YN
Cycle 1		9:23AM	4:06PM		?ass	PON
Cycle 2	i	4:12PM	9:35AM	,		
Cysic s	-	A. 1. 1001 -01-07 1-15-1 000	4:09714		Pass Pass	(2) N (7) N
Coot/Heat		***************************************	· manuelle institution and code		. 4740	TON
Cypte 1]	C:CJAW	- CoPN		Page	724
Cycle 2	7	S.CCAM	HIZOPM	······································		(V) ::
Oyelo S	<u>+</u>	9:UGAM	4:09FM		Pass	(DN
UV Stability	. ,,,,		terimente automorrique arpella		्रसम् सम्बद्धाः	(N
Cycle 1		000				
Cycle 2			2:00FM 4:00PM		188	MYZN
Cycle ši			10:00AM		P766	UN
Cycle 4			TO.OUM	* <u>}</u>	ail - Color change to yellow	YON
				150		1 4 14
The above enalysis w	vere completes	d by	Robat Kesla		•	
	· ·				•	
THE BUOVE BRIBISIS, I	aboratory note	thocks and	d pertinant int	formation was.	ratiowad and the results vernied by	
· —	A ST Page		E	,	on	•
This product (PASS	(FAIL) ho -h-		0 7	0 "		
1,1100	(FILE HE SEC	AN SINDIN	A restricter		DATE	#1.h





Tel: Fax:

FACSIMILE COVER PAGE

To: Christine (Business Fax)	From: Zane Last		
Fax #:	Fax #:		
Company: Red Rocks Laboratories, Inc.	Tel #:		
Subject: Scar Guard & Validation			
Sent:	Pages: 1 (including cover)		

MESSAGE:

Christine,

We are able to verify the amount of hydrocortisone in the collodion base as part of the validity and stability testing. While your clinical testing on psoriasis indicated that there was a transfer of the corticosteroid into the skin, your request to assay the actual potency of the delivery of corticosteroids for skin conditions such as psoriasis and eczema would have to be outsourced as they involve either animal or human studies.

Please let me know if you would like us to send this out for quotes.

Thank You,

Zane Last R. Ph.

Confidentiality Notice

This communication is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, or the employee or the agent for delivering the communication to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone call and return the communication to the address above via the United States Postal Service. Thank you.